Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis

Abstract

In this pooled analysis, benefit from PARPi appeared greatest for patients with <i>BRCA1</i>m, <i>BRCA2</i>m, <i>CDK12</i>m, and <i>PALB2</i>m. Given limitations of this exploratory analysis, the apparent lack of benefit from PARPi in patients with <i>CHEK2</i>m or <i>ATM</i>m should be further explored in future clinical trials.